Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Longer follow-up from the phase 3 INDIGO trial confirms that vorasidenib significantly reduces seizure rates in patients with grade 2 IDH-mutant glioma — but the benefit is largely driven by those with oligodendroglioma. Patients with astrocytoma saw little to no seizure reduction. Researchers also found that larger tumors and disease progression were both tied to higher seizure burden.
Extended follow-up data from the phase 3 INDIGO trial, presented at the 2026 SNO Annual Meeting, show that vorasidenib (Voranigo) continues to meaningfully reduce seizure rates in patients with grade 2 IDH-mutant glioma — but the benefit isn't uniform across tumor types. Among patients who had experienced at least one seizure, those on vorasidenib had a seizure rate of 15.9% per person-year, compared to a significantly higher rate in the placebo group (rate ratio 0.28; P = .0002).
That benefit was almost entirely driven by patients with oligodendroglioma, who saw a dramatic reduction in seizure rates (rate ratio 0.09; P < .0001). Patients with astrocytoma showed no statistically significant improvement. Researchers also found a clear link between tumor burden and seizures — bigger tumors meant more seizures, and disease progression was associated with seizure rates more than triple those seen during progression-free periods (rate ratio 3.74).
Key Takeaways
Why it matters: For neuro-oncologists managing grade 2 glioma, these findings reinforce that controlling tumor growth with vorasidenib may carry meaningful downstream benefits for seizure burden and quality of life — particularly in oligodendroglioma patients.